GlassScriptPhysician profile
Waylon A Steele
NPI 1730627944
$14,569.96
in general payments reported to CMS, 2019-2025
31 companies · $5,820 in 2025
The $5,820 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,572 · 2022: $1,233 · 2023: $2,727 · 2024: $3,218 · 2025: $5,820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,951 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,350 · Consulting Fee: $2,263 · Education: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,950.77 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,350.00 |
| Consulting Fee | $2,262.50 |
| Education | $201.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $6,569.81 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Janssen Biotech, INC. | $4,135.74 | 2021-2025 | Tremfya |
| Abbvie INC. | $914.18 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $594.33 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $356.97 | 2021-2025 | |
| Ucb, INC. | $238.71 | 2023-2025 | Bimzelx |
| Vyne Pharmaceuticals INC. | $206.79 | 2021 | |
| Genzyme Corporation | $200.72 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $141.60 | 2021-2023 | Winlevi, Absorica Ld |
| Solta Medical, A Division of Bausch Health US, LLC | $129.86 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $128.43 | 2021-2022 | |
| Lilly USA, LLC | $104.91 | 2021-2025 | Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $95.90 | 2024-2025 | Sotyktu |
| Incyte Corporation | $92.59 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $64.78 | 2021-2025 | Adbry |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $61.51 | 2025 | |
| Genentech USA, INC. | $58.41 | 2021-2024 | Erivedge |
| Pfizer INC. | $56.99 | 2021-2024 | |
| Dermavant Sciences, INC. | $52.04 | 2023 | Vtama |
| Verrica Pharmaceuticals INC. | $46.86 | 2023-2025 | Ycanth |
| Epi Health, LLC | $45.54 | 2022 | |
| Botanix Sb INC | $44.13 | 2025 | Sofdra |
| Journey Medical Corporation | $38.01 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.50 | 2024-2025 | Spevigo |
| Amgen INC. | $29.32 | 2021-2023 | Otezla |
| Merz North America, INC. | $26.72 | 2025 | |
| Paratek Pharmaceuticals, INC. | $26.20 | 2025 | Nuzyra |
| Organogenesis INC. | $23.46 | 2024 | |
| Almirall LLC | $21.91 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $17.87 | 2025 | Valchlor |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waylon Steele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.